| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514110300 | Growth hormone (GH) or derivative | 66 |
| 20100317581 | Ipamorelin Diacetate Injection and Infusion Solutions - Injection and infusion solutions of ipamorelin, having the following composition:
| 12-16-2010 |
| 20110053848 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L | 03-03-2011 |
| 20110077199 | GROWTH HORMONE POLYPEPTIDES AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions. | 03-31-2011 |
| 20110152190 | ERODIBLE POLYMERS FOR INJECTION - A composition for administration of a beneficial agent, contains a solvent mixture including a hydrophobic solvent and a hydrophilic solvent; a bioerodible polymer; and a beneficial agent. The polymer and the beneficial agent are dissolved. The composition has a low viscosity, allowing for easy injection through standard hypodermic needles. | 06-23-2011 |
| 20110257097 | PHARMACEUTICAL COMPOSITIONS OF SOMATOTROPHIC HORMONES - The invention provides a composition comprising (i) a somatotrophic hormone; (ii) a biodegradable polymer component; and (iii) a release modifier. A process for preparing, and the use of such a composition are also provided. | 10-20-2011 |
| 20110263501 | Growth Hormone Conjugate with Increased Stability - Novel growth hormone conjugates comprising a growth hormone compound (GH) and a growth hormone binding protein (GHBP) are disclosed. The invention also encompasses a novel derivatization method for producing stable, long-lasting conjugate (hGH-GHBP) by site specific conjugation. The novel GH-GHBP conjugates have an extended half-life in circulation that facilitates therapeutic use of the protein. The GH-GHBP conjugates exhibit pharmacological properties such as increased functional in vivo half-life, improved renal filtration, improved protease protection and albumin binding. | 10-27-2011 |
| 20110306548 | STABLE GROWTH HORMONE COMPOUNDS - The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation. | 12-15-2011 |
| 20120071409 | Colloidal Liposomal Compositions and Methods - A formulation delivery system is disclosed. When configured as a pro-liposome oral tablet, the tablet comprises a blend of at least one Iiposome forming ingredient, at least one active ingredient and at least one co-disintegrant. After ingestion at least a portion of the tablet disintegrates in a portion of an alimentary system to provide one or more in situ Iiposome encapsulated active ingredients. A method of producing the pro-liposome oral tablet and a method of therapeutically dosing with the pro-liposome oral tablet are further disclosed. The formulation delivery system may be configured as any one of a pro-liposome oral tablet, sublingual tablet, caplet, capsule and aerosol. | 03-22-2012 |
| 20120077745 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues - The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H | 03-29-2012 |
| 20120264691 | MEDICAL COMPOSITIONS CONTAINING GHRELIN - It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 6 μmol/mL. | 10-18-2012 |
| 20120322735 | MODIFIED GROWTH HORMONE POLYPEPTIDES - We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess. | 12-20-2012 |
| 20120329714 | Prolactin Induced Increase in Neural Stem Cell Numbers - The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions. | 12-27-2012 |
| 20130023477 | GROWTH HORMONE FUSION PROTEINS - We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers. | 01-24-2013 |
| 20130143815 | GROWTH HORMONE CONJUGATES - The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant. | 06-06-2013 |
| 20130157952 | GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO GROWTH HORMONE (GH) THERAPY - The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping. | 06-20-2013 |
| 20140073570 | PHARMACEUTICAL COMPOSITION AND METHODS FOR PEPTIDE TREATMENT - Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier. | 03-13-2014 |
| 20140088012 | GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO 2 YEARS OF GROWTH HORMONE (GH) THERAPY - The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping. | 03-27-2014 |
| 20140162953 | USE OF INHALABLE POWDER FORMULATION COMPRISING GROWTH HORMONE FOR PREVENTING OR TREATING NMDA RECEPTOR HYPOFUNCTION-RELATED DISEASES - A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided. | 06-12-2014 |
| 20140287997 | USE OF GROWTH HORMONE OR GROWTH HORMONE RECEPTOR AGONISTS TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS - The invention relates to methods for treating stress sensitive condition, particularly depression. For instance a subject having or at risk of having a stress-sensitive condition such as depression may be treated with a growth hormone (GH) or an agonist thereof in an effective amount to treat depression. | 09-25-2014 |
| 20140336117 | MODIFIED RECEPTOR FUSION PROTEINS - We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists. | 11-13-2014 |
| 20150072934 | METHODS OF PRODUCING ANAMORELIN HYDROCHLORIDE HAVING CONTROLLED CHLORIDE CONTENT - The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms. | 03-12-2015 |
| 20150080306 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 03-19-2015 |
| 20150133383 | METHOD FOR DIAGNOSIS AND TREATMENT OF PROLACTIN ASSOCIATED DISORDERS - The present invention concerns methods and tools for determining a specific treatment of a prolactin associated disorder. The treatment is selected based on the expression pattern of growth hormonereceptor (GHR), prolactin receptor (PrlR) and the suppressors SOCS2 and TCS2. | 05-14-2015 |
| 20160058879 | Growth Hormone Compound Formulation - The present inventions relates to compositions of growth hormone compounds, including pharmaceutical formulations. The compositions are able to provide initial and long term stability of the growth hormone compounds, rendering such compositions suited for use as a pharmaceutical formulation. | 03-03-2016 |
| 514110400 | Human growth hormone (hGH) or derivative | 42 |
| 20100261650 | RECOMBINANT FUSION PROTEINS TO GROWTH HORMONE AND SERUM ALBUMIN - The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally, the invention describes compositions comprising the albumin fusion proteins, and methods of treating patients in need of growth hormone, comprising administering the albumin fusion proteins of the invention. | 10-14-2010 |
| 20100305036 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS - The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy. | 12-02-2010 |
| 20110071080 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 03-24-2011 |
| 20110077200 | COMBINATION THERAPY USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - A composition comprising doxepin, or a pharmaceutically acceptable salt, or prodrug thereof, and a compound that enhances sleep onset, sleep maintenance or reduces early morning awakenings. These compositions are useful for treating multiple manifestations of insomnia. | 03-31-2011 |
| 20110112021 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS - A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial. | 05-12-2011 |
| 20110118183 | N-GLYCOSYLATED HUMAN GROWTH HORMONE WITH PROLONGED CIRCULATORY HALF-LIFE - The present invention relates to novel human growth hormone (hGH) variant(s) with one or more N-glycans. The hGH variants of the invention comprises an amino acid sequence which includes at least one N-glycosylation motif (N-X-S/T) arising from one or more mutations not present in the wild type hGH. The hGH variants of the invention have a prolonged circulatory half-life and thus can be effectively used as a protein therapeutic for disease states that will benefit from increased levels of hGH. The process of obtaining the hGH variants is also encompassed by the invention. | 05-19-2011 |
| 20110130331 | Modified growth hormones - Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides. | 06-02-2011 |
| 20110144017 | Protein conjugates and methods for their preparation - Reductive amination of peptide-derived aldehydes with anilines or heteroarylamines containing a property-modifying group provides new, hydrolytically stable protein conjugates, suitable for therapy. | 06-16-2011 |
| 20110195899 | Formulations of Human Growth Hormone Comprising a Non-Naturally Encoded Amino Acid - Formulations of modified human growth hormone polypeptides are provided. | 08-11-2011 |
| 20110230408 | HUMAN GROWTH HORMONE AQUEOUS FORMULATION - A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations. | 09-22-2011 |
| 20110237509 | hGH AND METHODS FOR PREPARING hGH - Preparations of recombinant human growth hormone (hGH) are provided having a purity that comprises 2% or less of a peptide other than native human growth hormone (e.g., essentially free of multimeric forms) are disclosed. Active pharmaceutical ingredient (API) preparations of recombinant hGH suitable for commercial production of formulation grade recombinant hGH are provided. A stable Master Cell Bank of transformed | 09-29-2011 |
| 20110257098 | COMPOSITIONS AND METHODS FOR TREATING GROWTH HORMONE DEFICIENCY - The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping. | 10-20-2011 |
| 20110281800 | RECOMBINANT FUSION PROTEINS TO GROWTH HORMONE AND SERUM ALBUMIN - The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally, the invention describes compositions comprising the albumin fusion proteins, and methods of treating patients in need of growth hormone, comprising administering the albumin fusion proteins of the invention. | 11-17-2011 |
| 20120088724 | Human Growth Hormone Formulations - Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins. | 04-12-2012 |
| 20120108512 | STABLE PHARMACEUTICAL COMPOSITIONS OF PEPTIDE DERIVATIZED USING AN OXIME LINKER - The invention relates to stable pharmaceutical compositions comprising a therapeutic peptide derivatized with a property-modifying group, wherein the property-modifying group is conjugated to the peptide by use of a linker comprising an oxime bond. | 05-03-2012 |
| 20120122782 | COMPLEXATION OF METAL IONS WITH POLYPEPTIDES - Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of individual polypeptide molecules is reduced when aqueous media is introduced to such formulations, serving to stabilize the polypeptide. | 05-17-2012 |
| 20120149644 | COMPOSITIONS AND METHODS FOR TREATING GROWTH HORMONE DEFICIENCY - The present invention relates to methods of predicting the level of response to treatment with growth hormone in an individual having Growth Hormone Deficiency (GHD) or Turner Syndrome (TS). | 06-14-2012 |
| 20120172303 | Growth Hormones with Prolonged In-Vivo Efficacy - The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. | 07-05-2012 |
| 20120208754 | STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES - This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10 | 08-16-2012 |
| 20120289465 | USE OF INHALABLE POWDER FORMULATION COMPRISING GROWTH HORMONE FOR PREVENTING OR TREATING NMDA RECEPTOR HYPOFUNCTION-RELATED DISEASES - A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided. | 11-15-2012 |
| 20130040883 | STABLE GROWTH HORMONE COMPOUNDS - The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation. | 02-14-2013 |
| 20130165378 | METHOD OF TREATING HUMAN GROWTH HORMONE MEDIATED CONDITION - A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations. | 06-27-2013 |
| 20130196915 | AFFINITY HYDROGELS FOR CONTROLLED PROTEIN RELEASE - The present invention relates to novel porous matrix composites and formulations for controlled protein delivery and the uses therefor. The present invention also provides methods of synthesizing such protein delivery systems. The composites comprise affinity sites embedded in the matrix where the affinity sites are functionalized with nucleic acid aptamers having high affinity for proteins to be released. The aptamers function as binding affinity sites for the proteins to be released. In certain embodiments, release rates are controlled by tuning the binding affinity of the nucleic acid aptamers to the proteins at a desired level. In yet other embodiments, complementary oligonucleotides that hybridize with the aptamers are employed to trigger accelerated release of the proteins when desired. Various in situ injectable hydro gels functionalized with aptamers are provided for treating a condition and disease in a subject in need of a therapeutic protein. | 08-01-2013 |
| 20130210729 | NON-AQUEOUS OILY INJECTABLE FORMULATION EXHIBITING PRESERVATIVE EFFICACY - Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative. | 08-15-2013 |
| 20130217629 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins. | 08-22-2013 |
| 20130261059 | Compositions and Methods for the Diagnosis and Treatment of Primary Insulin-Like Growth Factor Deficiency (PIGFD) and Idiopathic Short Stature (ISS) - Compositions and methods for identifying patients at increased risk for PIGFD and ISS are disclosed. | 10-03-2013 |
| 20140031289 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF - The present invention relates to a thermosensitive phosphazene-based polymer having a degradation controllable ionic group, a use thereof, and a use thereof as a material for delivering bioactive substances. The phosphazene-based polymer according to the present invention has the thermosensitivity of showing the temperature-dependent sol-gel phase transition. Thus, it forms a gel phase at the body temperature when it is injected into the body to make it easy to control the release of bioactive substances such as drugs, and has the functional groups capable of making chemical bonds such as ionic bond, covalent bond, coordinate bond, etc. with drugs and thus is excellent in bearing the drugs. Since it can control the degradation rate depending on the kind of ionic group, it can selectively control the release time depending on the characteristics of drugs. Furthermore, it has an excellent biocompatibility and thus is very useful as a material for delivery of bioactive substances such as drugs, etc. | 01-30-2014 |
| 20140045753 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS - The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications. | 02-13-2014 |
| 20140088013 | Complexation of Metal Ions with Polypeptides - Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of individual polypeptide molecules is reduced when aqueous media is introduced to such formulations, serving to stabilize the polypeptide. | 03-27-2014 |
| 20140113864 | Injectable Depot Composition - Gel compositions are provided that can be utilized as carriers for beneficial agents when injected into a subject and which can provide sustained release of the beneficial agent over time. In particular, gel compositions containing an agent that renders the composition thixotropic to facilitate injection of the gel into a subject with minimal discomfort to the subject are described. | 04-24-2014 |
| 20140162954 | FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN FORMULATION AND USES THEREOF - The present invention provides a method of treating a human patient in need of growth hormone therapy by periodically administering to the human patient for more than two weeks an effective amount of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO:1, so as to thereby treat the human patient. The present invention also provides a method of treating a human patient in need of growth hormone therapy by administering to the human patient, in a clinically effective regimen, a clinically effective dose of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO:1, wherein the clinically effective dose and clinically effective regimen are selected by a series of steps. | 06-12-2014 |
| 20140194356 | AQUEOUS FORMULATION COMPRISING AT LEAST A NEUTRAL SALT AND A BIOPHARMACEUTICAL PROTEIN - The present invention is related to a pharmaceutically acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of ≧0.7 and ≦5. | 07-10-2014 |
| 20140274900 | USE OF ANTAGONISTS OF GROWTH HORMONE OR GROWTH HORMONE RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS - The invention relates to methods for treating stress sensitive condition. For instance a subject having or at risk of having a stress-sensitive condition may be treated with a growth hormone (GH) antagonist in an effective amount to treat the stress sensitive condition. The GH antagonist may be, for instance, a growth hormone receptor (GHR) antagonist. | 09-18-2014 |
| 20140296145 | Modified Human Growth Hormone Polypeptides and Their Uses - Modified human growth hormone polypeptides and uses thereof are provided. | 10-02-2014 |
| 20140329750 | Growth Hormones with Prolonged In-Vivo Efficacy - The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. | 11-06-2014 |
| 20140364367 | METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER - This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels. | 12-11-2014 |
| 20150038415 | PROCESS FOR THE MANUFACTURING OF A DRUG DELIVERY SYSTEM BASED ON A POLYMER COMPRISING A DISPERSED BIOACTIVE AGENT - Process for the manufacturing of a drug delivery system based on a polymer comprising dispersed bioactive agent via the following process steps: (a) dissolving a polymer in an organic solvent (b) mixing the dissolved polymer with the bioactive agent (c) laminating the mixture between two polymer sheets, whereby at least one of the sheets is permeable to the organic solvent, to provide a film whereby the film can be further processed into the drug delivery system. The drug delivery system is suitable for implantation or injection and comprises fibres, rods, discs, coatings, tubes, films or rolled films. The polymer comprising the dispersed bioactive agent is a biostable, bioerodable or biodegradable polymer selected from the group consisting of polyesteramides, polythioesters, polyesterurethanes, polyesterurea's, PLLA, PLGA, polyesters, polyanhydrides, polycarbonates, polyurethanes, poly (amino acids), polypeptides, polyamides, polysaccharides, polyethers, polysulfones, poly(meth)acrylates, polysiloxanes, polyolefins. | 02-05-2015 |
| 20160015631 | OCULAR DRUG DELIVERY SYSTEM - An ocular drug delivery system can include a composition in which a formulation including recombinant human growth hormone (rHGH) is contained in a polymer matrix. The composition is configured for placement in or on the eye of a subject, and provides controlled release of an amount of the rHGH to the eye effective to promote healing of a conjunctival, sclera and or corneal wound. | 01-21-2016 |
| 20160015789 | FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN - A stable liquid pharmaceutical composition comprising an albumin-human growth hormone (hGH) fusion protein whose amino acid sequence is set forth as SEQ ID NO: 1 and a buffer, wherein the stable liquid pharmaceutical composition has a pH range of 5.5-6.5. | 01-21-2016 |
| 20160095904 | STABILIZED LIQUID FORMULATION - The present invention relates to a liquid formulation comprising an active substance and protamine, wherein the liquid formulation differs from a suspension. | 04-07-2016 |
| 20160158321 | TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY WITH HUMAN GROWTH HORMONE ANALOGUES - The present invention concerns a pediatric growth hormone deficiency (PGHD) therapy for pediatric subjects. The therapy comprises administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein in therapeutically effective doses every week, every two weeks, semimonthly, every three weeks, or monthly. This therapy is not inferior compared to the height velocity achieved with daily injections of hGH not linked to XTEN over the same period. | 06-09-2016 |
| 20160193285 | ORAL OCTREOTIDE ADMINISTERED IN COMBINATION WITH OTHER THERAPEUTIC AGENTS | 07-07-2016 |
